Acevedo Ribó M, Moreno Planas J M, Sanz Moreno C, Rubio González E E, Rubio González E, Boullosa Graña E, Sanchez-Turrión V, Sanz Guajardo D, Cuervas-Mons V
Department of Nephrology, Hospital Puerta de Hierro, Madrid, Spain.
Transplant Proc. 2005 Apr;37(3):1480-1. doi: 10.1016/j.transproceed.2005.02.002.
Pruritus is the most disabling symptom in patients with cholestatic liver diseases. Many drug therapies have been used for the treatment of these diseases, with different outcomes. The molecular adsorbent recirculating system (MARS) has been used in the treatment of intractable pruritus in cholestatic syndromes. We report our experience with MARS in 3 patients with intractable pruritus on the waiting list: 2 liver transplant recipients and a patient with primary biliary cirrhosis.
Two middle-aged women and 1 middle-aged man, who were recipients of an orthotopic liver transplant for primary biliary cirrhosis, underwent three (n = 2) and two (n = 1) 6-hour sessions of MARS due to medically uncontrollable pruritus. All noted marked improvement of pruritus, with decreased bilirubin levels, but this improvement lasted only a few days in all cases. We observed no changes in transaminase or albumin levels, or prothrombin time. Complications included an episode of angina due to anemia caused by jugular catheter bleeding, and thrombocytopenia in all patients.
MARS is an effective treatment for intractable pruritus in cholestatic liver diseases, although its beneficial effect is short. This extracorporeal liver device is safe, because most related adverse events are mild.
瘙痒是胆汁淤积性肝病患者最令人苦恼的症状。许多药物疗法已用于治疗这些疾病,但效果各异。分子吸附再循环系统(MARS)已用于治疗胆汁淤积综合征中的顽固性瘙痒。我们报告了我们对3例等待名单上患有顽固性瘙痒患者使用MARS的经验:2例肝移植受者和1例原发性胆汁性肝硬化患者。
两名中年女性和一名中年男性因原发性胆汁性肝硬化接受原位肝移植,由于药物无法控制的瘙痒,分别接受了三次(n = 2)和两次(n = 1)6小时的MARS治疗。所有患者均指出瘙痒明显改善,胆红素水平降低,但所有病例中这种改善仅持续了几天。我们观察到转氨酶、白蛋白水平或凝血酶原时间没有变化。并发症包括因颈静脉导管出血导致贫血引起的心绞痛发作,以及所有患者均出现血小板减少症。
MARS是治疗胆汁淤积性肝病顽固性瘙痒的有效方法,尽管其有益效果是短暂的。这种体外肝脏装置是安全的,因为大多数相关不良事件都很轻微。